New Trial: Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Trial Overview

NCT ID: NCT06480201 Phase: PHASE1 Enrollment Target: 100 Status: Recruiting

The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relative importance of GBP to antidepressant symptom reduction across the induction phase of treatment. If successful, it provides a compelling rationale for a larger prospective investigation of gamma dynamics as a moderator of outcome to varied TRD therapies which impact the balance of cortical excitation and inhibition.

Why This Matters

[Draft — editorial context needed]

Source

• View full trial on ClinicalTrials.gov